CorMedix Inc
NASDAQ: CRMD · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
CorMedix Inc (CRMD) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2008 | — | $-9.00M | — | — | — |
| 2009 | — | $-8.12M | — | — | — |
| 2010 | — | $-10.91M | — | — | — |
| 2011 | $0.00 | $-6.71M | — | — | — |
| 2012 | $0.00 | $-3.43M | — | — | — |
| 2013 | $2000.00 | $-9.13M | -9,980.20% | -245,769.75% | -456,654.90% |
| 2014 | $189274.00 | $-20.45M | -135.53% | -4,703.30% | -10,806.25% |
| 2015 | $210130.00 | $-18.19M | -51.68% | -7,925.56% | -8,655.37% |
| 2016 | $224105.00 | $-24.64M | -63.62% | -11,048.80% | -10,996.46% |
| 2017 | $329327.00 | $-33.01M | 65.09% | -9,997.39% | -10,023.45% |
| 2018 | $429797.00 | $-26.83M | 7.68% | -6,250.44% | -6,242.40% |
| 2019 | $283266.00 | $-16.43M | -31.76% | -7,416.31% | -5,801.29% |
| 2020 | $239231.00 | $-22.03M | 14.37% | -11,378.44% | -9,207.70% |
| 2021 | $190936.00 | $-28.21M | 22.00% | -15,417.51% | -14,774.70% |
| 2022 | $65408.00 | $-29.70M | 94.29% | -46,819.91% | -45,409.90% |
| 2023 | $0.00 | $-46.34M | — | — | — |
| 2024 | $43.47M | $-17.93M | 92.66% | -51.43% | -41.24% |
| 2025 | $311.71M | $163.06M | 88.46% | 48.17% | 52.31% |
Frequently asked questions
What is CorMedix Inc's revenue?
CorMedix Inc's trailing twelve-month revenue is $400.05M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is CRMD?
In its most recent fiscal year, CRMD ran a gross margin of 88.46%, an operating margin of 48.17%, and a net margin of 52.31%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does CRMD generate?
CRMD produced $172.79M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is CRMD's balance sheet healthy?
CRMD holds $145.82M in cash and equivalents against $144.63M in long-term debt, on $405.31M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.